Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of denosumab in men receiving androgen-deprivation therapy for non-metastatic prostate cancer
NL-OMON36983Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denosumab in osteoporosis and prostate cancer (PCa), sponsored by Amgen. Primary endpoint: Long-term safety profile of denosumab. Started Oct 2009; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosisprostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON36983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36983.